Midi Health vs Hers: Clinical Comparison

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Midi Health and Hers both operate telehealth GLP-1 platforms, but they differ meaningfully in clinical depth, medication selection, and support infrastructure. Both claim streamlined access; neither offers the same precision-guided approach that genetic insight can provide.

Choosing between them—or exploring alternatives—requires understanding not just cost and eligibility, but how your individual biomarker profile and genetic predispositions in GLP-1 pathways may influence medication response and side-effect tolerance. This precision-wellness lens shifts the conversation from one-size-fits-all to truly personalized.

Clinical Assessment Depth: How Each Platform Evaluates Patients

Midi Health conducts detailed metabolic screening, including fasting glucose, insulin, lipids, and weight-loss history. Hers uses a briefer questionnaire-based intake without routine labs. This difference matters: deeper metabolic data can reveal insulin resistance severity, which influences GLP-1 efficacy predictions and side-effect risk.

Neither platform currently integrates genetic testing into their standard workflows. A qualified provider can order standalone genetic testing—such as the Precision Peptide Genetic Test—to reveal predispositions in GIPR, GLP1R, FTO, and MC4R variants that may inform medication selection and expected metabolic response.

Medication Options, Formulations, and Cost Structure

Midi Health offers compounded semaglutide and tirzepatide, with monthly costs ranging $199–$349 depending on dose and compound. Hers primarily focuses on branded or compounded semaglutide, typically $199–$259 monthly. Both vary pricing by state, pharmacy network, and insurance status. Understanding what you're actually paying for—active ingredient strength, pharmacy source, and ongoing support—is critical.

Factor	Midi Health	Hers	PlexusDx Compounded Options
Primary GLP-1 Medications	Semaglutide, Tirzepatide	Semaglutide (branded/compounded)	Semaglutide $149/mo; Tirzepatide $249/mo
Lab Work Baseline	Comprehensive metabolic panel	Questionnaire-based only	Optional; genetic test $99 add-on or $298 standalone
Medication Formulation	Compounded injectable	Branded or compounded	Compounded 503A pharmacy-sourced only
Ongoing Provider Support	Monthly check-ins, dose titration	Telehealth visits as scheduled	Medically-supervised adjustments; genetic context available

Genetic and Biomarker Context: Why Individual Variation Matters

GLP-1 response varies significantly between individuals due to genetic polymorphisms in GLP1R, GIPR, FTO, and MC4R genes. A patient with certain GLP1R variants may achieve rapid satiety at lower doses, while another with FTO predispositions may metabolize glucose differently and require dose adjustments. Neither Midi Health nor Hers routinely tests for these.

Biomarkers like baseline fasting insulin, HbA1c, and inflammatory markers also predict side-effect frequency and treatment durability. A provider armed with both genetic and biomarker data can tailor medication selection, starting dose, and titration pace—moving beyond eligibility questionnaires toward evidence-informed personalization.

Safety Monitoring, Side Effects, and Provider Guidance

Both Midi Health and Hers offer telehealth follow-ups for symptom management, but depth varies. Hers typically schedules visits only when requested; Midi Health schedules regular monthly check-ins. GLP-1 side effects—nausea, vomiting, constipation, potential pancreatic or thyroid concerns—require active monitoring and dose adjustment, particularly in the first 8–12 weeks.

A healthcare provider familiar with your genetic predispositions can anticipate side-effect risk and adjust dosing proactively. For example, patients with certain GIPR or GLP1R variants may experience more pronounced gastric symptoms earlier, warranting slower titration or supportive pharmacotherapy. Genetic context supports safer, more tolerable treatment journeys.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing your genetic predispositions in four key GLP-1 pathway variants: GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These insights are not diagnostic and do not predict exact medication response, but they can support a more informed conversation with your provider about which GLP-1 compound and dosing strategy align with your metabolic profile.

The genetic test costs $99 as an add-on during PlexusDx product consultation or $298 standalone. Results should be interpreted with a qualified healthcare provider who can contextualize genetic findings alongside your lab work, medical history, and clinical goals. Knowing your genetic predispositions allows your provider to anticipate metabolic responses and potential side effects rather than relying on trial-and-error dosing.

When evaluating Midi Health, Hers, or other GLP-1 platforms, ask whether your chosen provider will integrate genetic or biomarker data into their assessment. PlexusDx makes this precision-guided approach standard, pairing compounded medications from licensed 503A pharmacies with actionable genetic insights that inform safer, more personalized treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Midi Health and Hers?

Midi Health conducts detailed metabolic labs and offers both semaglutide and tirzepatide with monthly check-ins ($199–$349/mo). Hers uses questionnaire-based intake, focuses on semaglutide ($199–$259/mo), and schedules visits as requested. Midi offers deeper baseline assessment; Hers emphasizes convenience and lower entry friction.

Does either Midi Health or Hers offer genetic testing?

Neither platform routinely integrates genetic testing into their standard workflows. However, a qualified provider can order standalone genetic testing—such as the Precision Peptide Genetic Test—to reveal GIPR, GLP1R, FTO, and MC4R predispositions that may inform medication selection and personalization.

How does PlexusDx compare on cost and features?

PlexusDx offers compounded semaglutide ($149/mo) and tirzepatide ($249/mo) from licensed 503A pharmacies. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) provides genetic context for personalization—a feature neither Midi Health nor Hers offers as standard.

Which platform is safer for GLP-1 treatment?

Safety depends on baseline health assessment, ongoing monitoring, and dosing adjustment. Midi Health's routine labs and monthly check-ins support active monitoring. Hers relies on patient-initiated follow-ups. Genetic predisposition data—available through PlexusDx testing—can help providers anticipate side effects and adjust dosing proactively f...

Can genetic testing predict which GLP-1 medication will work best for me?

Genetic testing reveals predispositions in GLP-1 pathways, not exact medication response. Results should be interpreted with a qualified provider alongside your labs, medical history, and metabolic profile. This context may help tailor starting dose, titration pace, and medication choice—but does not guarantee outcomes.

Midi Health vs Hers: Clinical Evidence and Personalization Factors